Indian Immunologicals Clarifies Status of NSQ Abhayrab Vials
By Business Desk
Indian Immunologicals Ltd confirms that rabies vaccine vials flagged as Not of Standard Quality were not manufactured by them, suspecting counterfeits.
Investigating the Vaccine Quality Alert
Indian Immunologicals Ltd (IIL) has issued a formal statement addressing reports concerning vials of its Abhayrab rabies vaccine labeled as Not of Standard Quality (NSQ). Following an internal review, the company confirmed that the specific batches identified by regulatory authorities did not originate from its manufacturing plants.
The company has identified the following primary concerns regarding these findings:
The batches flagged by regulators were not produced by IIL facilities. The organization suspects that the vials in question are counterfeit products currently circulating in the market.
Ensuring Safety and Market Integrity
IIL is actively collaborating with health authorities to investigate the origin of these non-compliant vials. The firm is prioritizing patient safety and the integrity of its supply chain during this process.
The company has issued the following directives for stakeholders:
Stakeholders are urged to verify the authenticity of all vaccine supplies. IIL remains committed to cooperating with regulators to address the circulation of these unauthorized products.
This verification process is essential to maintain public health standards and protect patients from potential risks associated with counterfeit medications. The company continues to monitor the situation to ensure that only genuine products reach the market.